Blood Screening Market By Product Type (Reagents & Kits, Instruments, Software), By Technology (Nucleic Acid Testing (NAT), ELISA, Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)), By Application (Infectious Disease Detection, Blood Group Typing, Cancer Detection, Metabolic Disorders, Drug Testing, Others), By End-user (Blood Banks, Hospitals, Clinical Laboratories, Plasma Donation Centers, Academic & Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Blood Screening Market accounted for USD 3.53 Billion in 2024 and is expected to reach USD 10.31 Billion by 2035, growing at a CAGR of around 10.23% between 2025 and 2035. The Blood Screening Market consists of the examination of blood samples for infectious diseases, blood type compatibility, and other health indications either before transfusion or clinical use. Safe blood supply and patient outcomes are heavily affected by such a procedure. A rise in the volume of blood donation across the globe and the rising prevalence of infectious diseases demanding early detection are driving factors within the market. Technological advancement improves screening efficiency and accuracy, with nucleic acid testing and automation experiencing a large contribution.

Report Scope:

Market Dynamics

Rising global blood donations increase the demand for safe and efficient screening methods.

Blood donations are steadily increasing worldwide, which is accompanied by a rising demand for methods of blood screening that are safe and effective. Participation in voluntary blood donation or replacement blood donation programs by greater numbers of individuals makes it very important that blood be safe. Blood screening is vital for the detection of transfusion-transmitted infections such as HIV, hepatitis B and C, and syphilis. The increase in voluntary blood donations has thus created a need for, besides these features, faster and more accurate as well as automated screening technologies. Governments and health bodies have put in place stringent rules that demand blood safety, and such development necessitates the increased investment in advanced diagnostics and screening infrastructure.

Increasingly, blood banks and hospitals have resorted to using advanced molecular diagnostic methods such as NAT for better sensitivity. There are also awareness campaigns by the government that have had positive effects on increasing contributions to demanding good quality reliability testing. The increase projected in the number of patients creates a need for blood associated with surgery, accident casualty treatment, and chronic illness care. Generally, it would appear that growth in donations translates directly into growth in the global Blood Screening Market.

The growing prevalence of infectious diseases fuels the need for advanced diagnostic technologies.

The burden of infectious diseases such as HIV, hepatitis B and C, Zika virus, and syphilis has pushed for the development and adoption of innovative blood screening diagnostic technologies. These diseases pose serious threats when transmitted through blood transfusion, thus requiring early and accurate detection. Conventional screening methods no longer meet today's healthcare needs. Instead, advanced molecular diagnosis such as Nucleic Acid Testing (NAT) and next-generation sequencing (NGS) have applications providing higher sensitivity and quite speedy results.

As global health challenges evolve, the pathogen complexities lead to a need for more intricate testing platforms. Automated systems are being embraced more and more by healthcare providers aiming at increasing throughput while reducing human errors. This trend is sharply reflected in high-burden areas wherein infectious diseases behave rampantly. Regulatory bodies have imposed stringent screening requirements, all of which are leaning toward technology adoption. Increased research funding for emerging pathogens is now flooding the market. Increased infectious diseases have emerged as one factor driving innovative technology.

The high cost of advanced screening technologies limits adoption in low-income healthcare settings.

The price tag associated with advanced blood-screening technologies restricts the overall market growth, especially in low-income and resource-strained healthcare settings. Some of these technologies, including NAT and automated ELISA systems, require a capital investment for their purchase, maintenance, and training. Many healthcare facilities in developing nations cannot afford the cost of advanced diagnostic equipment. Thus, the reliance on old or manual screening methods continues to dominate, yielding low accuracy and slow results, which directly affect the very essence of early disease detection and blood safety protocols.

With the funds in public health systems generally allocated to urgent patient care and less to upgrading diagnostic equipment, this leads to a further decrease in accessibility and clinical implementation. Furthermore, the absence of government subsidies or donor funding permits the aggravation of accessibility. The high operational costs do not encourage private laboratories to undertake the absorption of such equipment. In short, cost becomes a strong deterrent for blood screening services in underprivileged areas. The direct consequences of this cost deterrent hamper the global efforts to implement safe transfusion practices and prevent the spread of infectious diseases.

The expansion of healthcare infrastructure in developing regions boosts market penetration and accessibility.

The expansion of healthcare infrastructure in developing regions is making a remarkable opportunity for the Blood Screening Market. With investments in hospitals, clinics, and diagnostic labs from both the public and private sectors, the availability of advanced medical services is becoming more widespread. Thus, it allows for the application of modern blood screening technologies to standard healthcare services. Improved facilities also join hands with the capacity building of medical personnel to increase the efficiency, accuracy, and timely access of their clients in medical testing. More diagnostic facilities are provided for the use of more people in rural and underserved areas.

More access to diagnostics, making way for the early identification and management of diseases and enhancing public health overall. Apart from that, this availability of equipment and reagents in these areas would energize local demand stimulation. Therefore, infrastructure growth machines present great opportunities for international players. The blood screening industry thus will enjoy high adoption and sustainability for the long term in developing economies.

Increasing public awareness about blood safety enhances demand for comprehensive screening programs.

An increase in public awareness about blood safety will act as a powerful force for demand for full screening programs. With more people becoming aware of the impact of transfusion-transmitted infections, safe blood becomes a public health importance issue. Educative campaigns by governments, NGOs, and healthcare provide myths that dispel voluntary blood donation. This stresses rigorous screening before any transfusions. Educated donors and recipients will demand that health systems adopt higher-quality testing.

Creating this awareness has also been done very well through the media and online platforms. More trust in health institutions will increase participation in screening programs. Increased public demand for safety will subject healthcare facilities to greater pressure. In summary, activities like these drive the health sector to resituate itself to provide higher safety requirements. In the end, there would be greater implementation of such advanced technologies in screening. These dynamics produce a more challengeable and more efficacious market in blood screening or safety.

Industry Experts Opinion

“We are now in the era of the genome, where genomic sequencing is transforming healthcare through personalized therapies and gene-based medicine.”

• Francis deSouza, CEO of Illumina.

Segment Analysis

Based on the product type, the Blood Screening Market is classified into reagents and kits, instruments, and software and services. Among the three segments, it is expected that reagents and kits will occupy the most significant market share due to the repetitive usage of high volumes and their critical role in every test. NAT, ELISA, and rapid test kits will be administered to detect several infections. There will be steady growth in the instruments segment with increasing automation in laboratories and the adoption of high-throughput platforms. Commonly used instruments include PCR systems and immunoassay analyzers. Software and services are gaining pace, with laboratories opting for complete solutions for data management and workflow optimization. Growth has continued in every segment of the market, fueled by an increase in demand for fast, accurate, and reliable testing.

Based on the application, the Blood Screening Market is classified into infectious disease detection, blood group typing, cancer detection, metabolic disorders, and drug testing. Infectious diseases such as HIV, Hepatitis B and C, and Syphilis. Because of the great need for blood safety, this segment holds the greatest market share. Blood group typing is another important aspect considered in surgeries and emergencies. The detection period of cancer cells based on blood biomarkers is being pursued more vigorously with the development of liquid biopsy techniques. Screening for metabolic disorders is also crucial during the neonatal period and regular checkups. On the other hand, drug testing is increasing in the workplace, sports, and forensic applications. Awareness and investments in health care are pushing these applications. Increasing demand for early diagnosis is another driver of innovations in all the application areas.

Regional Analysis

With advanced healthcare infrastructure and high modern diagnostic technologies adoption among the population, North America emerges as the leader in the global Blood Screening Market. Considerable healthcare expenditure and a robust government ground in blood safety regulations characterize this region. It is no wonder that the United States will take the lion's share of the market, owing to extensive blood banks as well as diagnostic centers dispersed throughout the territory. Awareness campaigns accompanied by mandatory screening programs would penetrate the market further. Continuous technological advancement and a rapid switch toward molecular testing solutions enhance efficiencies for blood screening. Alliances and partnerships between substantial players in the sector will keep supporting the market to grow. North America will continue to helm the sector by stressing quality in healthcare.

The Asia Pacific Blood Screening Market is increasingly becoming a marketplace that is fast-growing across all continents. This is due to the rising awareness about healthcare and increasing emphasis on the best possible methods of blood transfusion. Increased government initiatives and investments in healthcare infrastructure are majorly supporting this growth. Rapid urbanization and improved access to healthcare facilities are further fueling demand in the market. It is causing great pressure on screening requirements because of the rising population and a growing incidence of infectious diseases. These advancements and the inclusion of modern approaches to diagnostics are growing rapidly in all countries across the regions. Countries such as China and India have greater donor representations and are backing up with supporting policies. This overall region hence stands promising for both manufacturers and healthcare providers.

Competitive Landscape

The Blood Screening Market competes to provide avant-garde diagnostic solutions by several key players. Beginning with F. Hoffmann-La Roche Ltd. (Switzerland) or Grifols S.A. (Spain), these companies have already formed strong footprints in the global landscape considering their wide portfolio and partnerships within it in extensive form. Some of the other prominent names in the market include Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation (Beckman Coulter), bioMérieux, Hologic, Thermo Fisher Scientific, Becton, Dickinson and Company, and Siemens Healthineers.

Such companies are investing in innovations, which reflect their development of technologies for the next decades, such as nucleic acid testing (NAT) or superior immunoassays. The market is consolidating through mergers and acquisitions to build the technological capabilities of these companies and expand market share. New entrants source novel solutions that stir competition and motivate advances in technology. Such a situation generally makes the competitive environment dynamic, as companies try to match the major growth in the number of consumers making up the world demand for blood screening.

Blood Screening Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2023, Siemens Healthineers launched two new analyzers, the Atellica HEMA 570 and Atellica HEMA 580, designed for high-volume hematology testing, crucial for blood screening. These advanced devices can streamline the complete blood count (CBC) process, offering rapid results and improved workflow efficiency. With the ability to process up to 120 tests per hour, these analyzers can address the growing demand for timely diagnostics in critical care settings.

Frequently Asked Questions (FAQs)